Panel - High-impact Applications of Model-based Meta-analyses (MBMA) in Drug Development

Panelist(s)

• 

  Matthew L. Zierhut, PhD, MBA (he/him/his)

  Vice President, Certara Drug Development Solutions
  Certara
  San Diego, California, United States
• 

  Monica Simeoni, PhD (she/her/hers)

  Senior Director, Clinical Pharmacology and Quantitative Medicine
  GSK, United Kingdom
• 

  Hongtao Yu, PhD (he/him/his)

  Associate Director, Clinical Pharmacology and Quantitative Pharmacology
  AstraZeneca, United States
• 

  Mats O. Karlsson, PhD, FISoP, FACCP (he/him/his)

  Professor
  Uppsala University, Sweden